Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # AVI1906

Biotinylated
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
AVI1906-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Learn more about Avi-tag Biotinylated Proteins

Source

HEK293

Accession #

Q9NQ25.1

Structure / Form

Disulfide-linked homodimer, biotinylated via Avi-tag

Conjugate

Biotin

Applications

Binding Activity, Bioactivity

View all CRACC/SLAMF7 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human CRACC/SLAMF7 protein
Human CRACC/SLAMF7
(Ser23-Met226)
Accession # Q9NQ25.1		 IEGRMD Human IgG1
(Pro100-Lys330)		 Avi-tag
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser23

Predicted Molecular Mass

51 kDa

SDS-PAGE

65-85 kDa, under reducing conditions

Activity

The biotin to protein ratio is greater than 0.7 as determined by the HABA assay.

Measured by its binding ability in a functional ELISA.
When Human CRACC/SLAMF7 Antibody (Catalog # MAB1906) is Immobilized at 1.0 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human CRACC/SLAMF7 Fc Chimera Avi-tag (Catalog # AVI1906) that produces 50% optimal binding response is found to be approximately 1.00-10.0 ng/mL.

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells.
The ED50 for this effect is 1-6 μg/mL.

Scientific Data Images for Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein, CF

Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein Binding Activity

Biotinylated Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein Binding Activity.

When Human CRACC/SLAMF7 Antibody (MAB1906) is immobilized at 1.00 µg/mL (100 µL/well), the concentration of Biotinylated Recombinant Human CRACC/SLAMF7 Fc Chimera Avi-tag (Catalog # AVI1906) that produces 50% optimal binding response is 1.00-10.0 ng/mL.
Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein SDS-PAGE

Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein SDS-PAGE

2 μg/lane of Biotinylated Recombinant Human CRACC/SLAMF7 Fc Chimera Avi-tag (Catalog # AVI1906) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 65-85 kDa and 130-170 kDa, respectively.

Formulation, Preparation and Storage

AVI1906
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 200 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CRACC/SLAMF7

CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CRACC consists of an extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a transmembrane segment, and a cytoplasmic domain with one immunoreceptor tyrosine-based switch motif (ITSM) (2, 3). Within the ECD, human CRACC shares 54% and 52% amino acid sequence identity with mouse and rat CRACC, respectively. There are seven known isoforms of CRACC which are distinguished by deletions and/or substitutions in both their ECD and cytoplasmic domains. CRACC is expressed on the surface of NK cells, CD8+ T cells, activated B cells, and mature dendritic cells (4, 5). Its homophilic interaction induces NK, CTL, and B cell activation (4-7). In human NK cells, activated CRACC transmits signals following association with the adaptor protein EAT-2 (8).Our Avi-tag Biotinylated Recombinant Human CRACC/SLAMF7 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References

  1. Veillette, A. (2006) Immunol. Rev. 214:22.
  2. Tovar, V. et al. (2002) Immunogenetics 54:394.
  3. Murphy, J.J. et al. (2002) Biochem. J. 361:431.
  4. Bouchon, A. et al. (2001) J. Immunol. 167:5517.
  5. Lee, J.K. et al. (2007) J. Immunol. 179:4672.
  6. Kumaresan, P.R. et al. (2002) Mol. Immunol. 39:1.
  7. Stark, S. and C. Watzl (2006) Int. Immunol. 18:241.
  8. Tassi, H. and M. Colonna (2005) J. Immunol. 175:7996.

Alternate Names

CD319, SLAMF7

Entrez Gene IDs

57823 (Human); 75345 (Mouse); 102133710 (Cynomolgus Monkey)

Gene Symbol

SLAMF7

UniProt

Q9NQ25.1

Additional CRACC/SLAMF7 Products

Product Documents for Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human CRACC/SLAMF7 Fc Avi-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.